Literature DB >> 16985746

Prostate size: does it matter?

C G Roehrborn.   

Abstract

Year:  2000        PMID： 16985746      PMCID： PMC1476114     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  6 in total

1.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Authors:  C G Roehrborn; P Boyle; A L Gould; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

2.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

Authors:  C G Roehrborn; J D McConnell; M Lieber; S Kaplan; J Geller; G H Malek; R Castellanos; S Coffield; B Saltzman; M Resnick; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

3.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

4.  Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials.

Authors:  P Boyle; A L Gould; C G Roehrborn
Journal:  Urology       Date:  1996-09       Impact factor: 2.649

5.  Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.

Authors:  C G Roehrborn; P Boyle; D Bergner; T Gray; M Gittelman; T Shown; A Melman; R B Bracken; R deVere White; A Taylor; D Wang; J Waldstreicher
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

6.  Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Authors:  R Bruskewitz; C J Girman; J Fowler; O F Rigby; M Sullivan; R B Bracken; H A Fusilier; D Kozlowski; S D Kantor; E L Johnson; D Z Wang; J Waldstreicher
Journal:  Urology       Date:  1999-10       Impact factor: 2.649
  6 in total
  2 in total

1.  Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.

Authors:  Lance W Middleton; Zhewei Shen; Sushama Varma; Anna S Pollack; Xue Gong; Shirley Zhu; Chunfang Zhu; Joseph W Foley; Sujay Vennam; Robert T Sweeney; Karen Tu; Jewison Biscocho; Okyaz Eminaga; Rosalie Nolley; Robert Tibshirani; James D Brooks; Robert B West; Jonathan R Pollack
Journal:  JCI Insight       Date:  2019-05-16

2.  Evaluation and management of male lower urinary tract symptoms: treatment patterns and guidelines in a correlation study among Polish urology consultants.

Authors:  Tomasz Borkowski; Tomasz Golabek; Piotr L Chlosta; Andrzej Borkowski
Journal:  Arch Med Sci       Date:  2015-12-11       Impact factor: 3.318
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.